Skip to content
value.today

Lipella Pharmaceuticals Inc.

LIPO
$6 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$1 M
For year ending December-2024
Net income
$-5 M
-929.6% margin
SEC filing
Employees
—

Lipella Pharmaceuticals Inc. in brief

Lipella Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in Pittsburgh, Pennsylvania, USA. Its last known market value was $6 M (January 2024); there is no current figure. In the year to December 2024 it had sales of $1 M and a net loss of $5 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lipella Pharmaceuticals Inc.

We are a clinical-stage biotechnology company that was incorporated under the laws of the State of Delaware in February 2005. We are focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.

We believe that our strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates. Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. We believe that this focus can potentially help reduce the cost, time and risk associated with obtaining marketing approval. We have not yet commercialized any products, and we do not expect to generate revenue from sales of any product candidates for several years.

From the company's annual report filed with the US SEC: read the report

Lipella Pharmaceuticals Inc. timeline

3 events, 2005–2024
  1. 2005
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 21 December 2022; shares registered for exchange trading on 19 December 2022.
  5. 2024
  6. 💰
    Record revenue of $1 million
    FY2024, the highest of the 4 years on record.

Events of Lipella Pharmaceuticals Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$6 M$12 M$19 M$25 M20232024

World rank over time

▼ down 3,397 places since 2022
2022-12-25: #28796#28,79620222023-07-30: #31020#31,02020232024-01-05: #32193#32,1932024

Rank in USA: #5,220 (Dec 2022) · #5,363 (Jul 2023) · #4,604 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-929.6%
Operating margin
-940.7%
Return on equity
-261.5%
Liabilities / assets
28.1%
Revenue growth
+20.0%
R&D / revenue
668.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue $0M, net income $-2M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-3M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-5M$0MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-5M$1MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$1M+20.0%$-5M$-5M-929.6%
Dec 2023$0M+150.0%$-5M$-5M-1026.7%
Dec 2022$0M-30.8%$-3M$-3M-1444.4%
Dec 2021$0M—$-2M$-2M-719.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-4M——$-4.79—
Dec 2023$-3M$0M$-3M$-6.16—
Dec 2022$-2M——$-0.64—
Dec 2021$-1M——$-0.55—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2023 (from the annual report): revenue $0M, net income $-1M$0MDec ’23Three months to Mar 2024: revenue $0M, net income $-1M$0MMar ’24Three months to Jun 2024: revenue $0M, net income $-1M$0MJun ’24Three months to Sep 2024: revenue $0M, net income $-1M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-1M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-1M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-1M$0MJun ’25Three months to Sep 2025: revenue —, net income $-1M—Sep ’25

Latest quarter to Sep 2025: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2025.

SEC filings

Official filings of Lipella Pharmaceuticals Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-5 M
Net income
$-5 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$3 M
Total liabilities
$1 M
Total equity
$2 M

As of December-2024

Insider trading at Lipella Pharmaceuticals Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
2
since
$45 K$0Mar 2024: bought $45 K (2 trades), sold $0 (0 trades)Mar 24May 2024: bought $8 K (1 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Lipella Pharmaceuticals Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jonathan H. KaufmanSee remarks below., Director, 10% ownerBuy+10,000$0.760$8 K898,849Form 4
filed Jonathan H. KaufmanSee remarks below., Director, 10% ownerBuy+25,000$0.870$22 K888,849Form 4
filed Jonathan H. KaufmanSee remarks below., Director, 10% ownerBuy+30,000$0.790$24 K863,849Form 4
filed Jonathan H. KaufmanSee remarks below., Director, 10% ownerGrant or award+144,906$0.690$100 K833,849Form 4
filed Michael B. ChancellorChief Medical Officer, Director, 10% ownerGrant or award+144,906$0.690$100 K877,637Form 4
filed Michael B. ChancellorChief Medical Officer, Director, 10% ownerOther+22,950$5.750$132 K732,730Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lipella Pharmaceuticals Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Bankruptcy filing: (8-K); (8-K)

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lipella Pharmaceuticals Inc. scorecard#

Passes 1 of the 6 checks that could be worked out. Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.79 vs -6.16Diluted EPS -4.79 in fiscal 2024 against -6.16 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2024.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-198.4%-198.4% in fiscal 2024.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.49 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year39.7%Diluted shares up 39.7% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Lipella Pharmaceuticals Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lipella Pharmaceuticals Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue536450184259
Research and development3,6133,0392,5481,457
General and administrative2,0042,157226718
Operating income−5,081−4,746−2,590−1,916
Interest and finance income641381.70.1
Interest expense and finance costs—119.66.8
Other non-operating income (expense)64127−8.050
Income before tax−5,016−4,619−2,598−1,865
Net income attributable to shareholders−5,016−4,619−2,598−1,865
Earnings per share, basic-4.79-6.16r-0.64-0.55
Earnings per share, diluted-4.79-6.16r-0.64-0.55
Shares, weighted average (basic)1.00.8r4.13.4
Shares, weighted average (diluted)1.00.8r4.13.4
Balance sheet
Cash and cash equivalents2,1853,2945,1221,414
Short-term investments———301
Receivables8532114—
Current assets2,6173,4295,7991,808
Property, plant and equipment9.913——
Right-of-use (leased) assets47135151205
Total assets2,6743,5775,9502,013
Accounts payable38813838447
Current liabilities7543851,178341
Lease liabilities (non-current)—4796168
Total liabilities7544331,275589
Retained earnings−15,340−10,324−5,705−3,107
Shareholders' equity1,9193,1444,6761,424
Total liabilities and equity2,6743,5775,9502,013
Shares outstanding1.20.8r5.7r3.9
Cash-flow statement
Depreciation and amortization2.91.7——
Cash from operating activities−3,951−3,150−1,831−989
Capital expenditure—−14——
Cash from investing activities—−14301−301
Shares issued——4,9642,097
Cash from financing activities2,8421,3375,2392,097
Report10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Lipella Pharmaceuticals Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Bankruptcy or receivershipFiling
  • Bankruptcy or receivershipFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

And 1 more in the list below.

Bankruptcy or receivership 2 · Delisting notice 5 · Directors and officers 3 · Material agreement 8 · Unregistered share sale 6 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 1

Lipella Pharmaceuticals Inc.: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivership8-K
Bankruptcy or receivership8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Delisting notice8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Shareholder vote8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 15, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Lipella Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$3 MPrivate placement after listing$2 to $10 million26equity, optionsSEC
Oct 2023$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Oct 2020$3 MNo. 1$2 to $10 million43equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Lipella Pharmaceuticals Inc. compares in Biotechnology

  • Revenue$1 M · higher than 21% of 647
  • Net margin-929.6% · higher than 1% of 408
  • Revenue growth20.0% · higher than 61% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Lipella Pharmaceuticals Inc.🇺🇸$6 M—-929.6%+20.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lipella Pharmaceuticals Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lipella Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lipella Pharmaceuticals Inc.? Suggest a correction